At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65,406 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists
In Brief
An observational study for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 65,406 participants across 1 site.
Detailed Summary
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for the treatment of COPD.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesDenmark
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionFeb 2020
TodayJul 2026
First PostedJan 23, 2018
Enrollment StartJan 31, 2018
Primary CompletionFeb 3, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 8.4 years ago